At FluoGuide, our mission is to help patients with cancer by improving precision surgery. Our lead product, FG001, has been clinically proven to light up cancer and guide surgeons in performing more precise surgeries.

The objective of the collaboration is to develop FG001 for tumor imaging and surgical margins assessment for head and neck cancer. The focus of the current agreement is to support the clinical phase and to gather a body of evidence on Olympus’s technology platforms used in combination with FG001.

The agreement has no initial payment and is non-exclusive. The terms of this agreement are not disclosed, and the agreement will not have an impact on the Company’s financial results in 2025.

"The cooperation between Olympus and FluoGuide represents a substantial opportunity to contribute to the advancement of fluorescence and molecular imaging,” says Simon Hirschfeld, Managing Director at Quest Medical Imaging, an Olympus Group Company. “Together, we look forward to shaping the future of research and innovation in this field and helping raise the standard of care for patients.”

"We’re thrilled to partner with Olympus, a global leader in medical technology. This collaboration is an exciting step forward in advancing precision cancer surgery for head and neck cancer. By combining FluoGuide’s FG001 technology with Olympus’s imaging systems, we’re working to improve surgical precision and deliver better outcomes for patients with cancer,” says Morten Albrechtsen, CEO of FluoGuide.